A Phase II Study with Cetuximab and Radiation Therapy for Patients with Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group G05-92  by Becerra, Carlos R. et al.
1425Journal of Thoracic Oncology ®  •  Volume 8, Number 11, November 2013
Introduction: On the basis of the promising activity of cetuximab 
and radiation therapy for head and neck cancers, we evaluated the 
efficacy of this regimen followed by surgery in patients with resect-
able esophageal cancer. This was a phase II, open-label, single-arm, 
multicenter study of patients with potentially resectable esophageal 
cancer.
Methods: Patients received two weekly doses of cetuximab followed 
by weekly cetuximab combined with radiation therapy for 6 weeks. 
After a 6- to 8-week rest, patients’ primary tumor was resected. The 
main objective was to evaluate pathologic complete response (pCR) 
rate in the primary tumor after cetuximab and radiation therapy.
Results: Thirty-nine patients completed the study. Most patients 
were men (93%), median age was 64 years, performance status was 
0 to 1 (95%), patients had a histology of adenocarcinoma (78%), and 
tumors were located in the esophagus (63%). Grade 3 toxicities in 
more than 5% of patients included dysphagia (17%), anorexia and 
dehydration (7%), and dyspnea, fatigue, hypernatremia (5%). Grade 
5 aspiration occurred in 2% (1 patient). Four patients died, two from 
disease progression, one from aspiration pneumonia postsurgery, and 
one from septic shock. Thirty-one patients (76%) underwent esopha-
gectomy. The pCR rate was 36.6% by intention-to-treat and 48% for 
patients who underwent esophagectomy. The pCR by histology was 
6 of 9 (67%) for squamous cell carcinomas and 9 of 32 (28%) for 
adenocarcinoma. Earlier-stage disease was associated with increased 
pCR (IIA 70%, IIB 29%, III 28%).
Conclusions: Cetuximab and radiation therapy results in a pCR rate 
that seems at least comparable with that of chemotherapy and radia-
tion therapy. This regimen may be better tolerated than preopera-
tive chemotherapy and radiation therapy in patients with resectable 
esophageal cancers.
(J Thorac Oncol. 2013;8: 1425–1429)
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Esophageal carcinomas in 2012 affected 17,460 Americans, resulting in an estimated 15,070 deaths.1 One standard 
approach for the management of patients with resectable 
esophageal cancer involves trimodality therapy that includes 
chemotherapy with concurrent radiation therapy followed by 
surgical resection of the primary lesion with improved long-
term survival but marginal tolerance to treatment.2,3 Patients 
who cannot have surgical resection of the esophagus cancer 
can be treated with combined chemotherapy and radiation 
therapy with superior survival outcomes similar to those with 
radiation alone.4
The epidermal growth factor receptor (EGFR) signal-
ing pathway is an important target in esophageal cancers, 
and high EGFR expression by immunohistochemical score 
in the tumor of patients with resected esophageal adenocar-
cinomas after trimodality therapy predicts a poor outcome.5 
Cetuximab is a monoclonal antibody that binds to the EGFR 
and competitively inhibits the binding of epidermal growth 
factor and other ligands blocking phosphorylation and activa-
tion of receptor-associated kinases. EGFR inhibition results 
in Gap 1 cell-cycle arrest, and radiation results in Gap 2 cell-
cycle arrest, Gap 1 and Gap 2 being part of the interphase 
segment of cell growth. In preclinical models, EGFR inhi-
bition enhances radiation-induced apoptosis, inhibits repair 
of radiation-induced DNA damage, and inhibits formation 
of new blood vessels.6 The radio-sensitizing effect of cetux-
imab has already been tested in patients with squamous cell 
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carcinomas of the head and neck, with improvement in local 
control, progression-free and overall survival over radiation 
therapy alone.7
Herein, we present the results of a single-arm, open-
label, phase II study with cetuximab and external beam radia-
tion therapy for patients with newly diagnosed, potentially 
resectable esophageal and gastroesophageal (GE) junction 
carcinomas, with the intent of improving efficacy and decreas-
ing toxicity over current standard treatment approaches.
MATERIALS AND METHODS
This was a phase II, open-label, single-arm, multicenter 
study that accrued patients with potentially resectable esopha-
geal cancer. The study was conducted in accordance with the 
Declaration of Helsinki and is consistent with International 
Conference on Harmonisation good clinical practice guide-
lines. The protocol was approved by the local institutional 
review boards/ethics committees, and all patients provided 
a written informed consent. The study was coordinated by 
the Hoosier Oncology Group Clinical Trials Working Group 
(Indianapolis, IN).
The primary objective of the study was to evaluate the 
pathologic complete response (pCR) rate in the primary tumor 
after cetuximab and radiation therapy. Secondary objectives 
were to evaluate the clinical complete and partial response 
rates, and overall toxicities.
Patients
Key inclusion criteria were the following: age more 
than 18 years; Eastern Cooperative Oncology Group (ECOG) 
performance status of 0 to 2; pathologic diagnosis of squa-
mous cell carcinoma or adenocarcinoma of the esophagus or 
GE junction; clinical stages IIA, IIB, III, or IVA with celiac 
node involvement; surgical candidates as determined by a 
surgical consult; patient being agreeable to surgical resec-
tion of the primary tumor; no prior use of radiation or che-
motherapy for cancer of the esophagus or GE junction; no 
prior therapy directed against the EGFR pathway; no major 
surgeries within 28 days of registration for protocol therapy; 
no other active malignancies; no history of uncontrolled car-
diac disease; no history of interstitial pneumonitis or pul-
monary fibrosis; and adequate marrow and organ function 
including absolute neutrophil count more than 1000 mm3; 
platelet count more than 75,000 mm3, hemoglobin more 
than 10 g/dl, creatinine less than two times the upper limit 
of normal (ULN), bilirubin less than 2.5 times ULN, aspar-
tate transaminase (SGOT), and/or alanine aminotransferase 
(SGPT) less than 5.0 times ULN; no prior severe infusion 
reaction to a monoclonal antibody; and use of an effective 
method of contraception.
Treatment
All patients received premedication with dyphenhydr-
amine hydrochloride at an initial dose of 50 mg by intrave-
nous infusion given 30 to 60 minutes before the first dose of 
cetuximab. Premedication with dyphenhydramine hydrochlo-
ride for subsequent doses of cetuximab was modified at the 
investigators’ discretion.
The initial dose of cetuximab was administered at 
400 mg/m2 intravenously over 120 minutes followed by 
weekly infusions of cetuximab at 250 mg/m2 over 60 min-
utes. Cetuximab was administered weekly for two doses. 
Radiation therapy was started after the second dose of 
cetuximab, and the combination of once-weekly cetuximab 
and radiation therapy was continued until the completion 
of radiation therapy. Total weekly cetuximab doses equaled 
eight.
External beam radiation therapy was started on week 
3 of cetuximab infusion to a total dose of 50.4 Gy divided 
into 1.8 Gy per fraction per day. Megavoltage equipment was 
required with effective photon energies at more than 6 MV. 
Twice weekly, the verification films of orthogonal views were 
reviewed by the treating physicians.
All study patients had a planned surgical resection of the 
primary tumor and adjacent mediastinal and/or celiac lymph 
nodes after satisfactory hematologic and functional recovery 
within 8 weeks of completion of radiation therapy. Lymph 
node staging performed at the time of laparoscopy or thora-
coscopy was repeated at the time of resection. Rather than 
simply sampling a site-representative node from each level, 
we removed all technically accessible lymph nodes.
Assessment
Efficacy
Patients had a baseline computed tomography scan of 
the chest, abdomen, and pelvis with repeat imaging performed 
after cetuximab and radiation therapy to exclude interim 
development of metastatic disease. Patients had a baseline 
upper endoscopy with ultrasound, pulmonary function tests, 
and tumor sampling. Clinical staging was reported according 
to the American Joint Commission on Cancer criteria ver-
sion 6.8 At the time of surgery, an evaluation of the primary 
sample was performed to determine complete pathologic 
response (defined as the absence of tumor cells in the resected 
specimen).
Safety and Tolerability
A safety evaluation was performed at baseline and then 
weekly for the duration of treatment. Patients were followed 
for 12 weeks after surgical resection or until resolution of 
treatment-related toxicities. Patients underwent a physical 
examination, vital signs, ECOG performance status, complete 
blood count, and chemistries as part of the safety evaluation. 
Toxicities were assessed according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events 
version 3.0,9 and this included assessment of dysphagia as 
follows:
Grade 0: None
Grade 1: Mild dysphagia but can eat a regular diet
Grade 2:  Dysphagia requiring predominantly liquids, pureed 
foods, or soft diet
Grade 3:  Dysphagia requiring a feeding tube, intravenous 
hydration, or parenteral hyperalimentation
Grade 4:  Complete obstruction (cannot swallow saliva); 
 ulceration with bleeding not induced by minor 
trauma or abrasion or perforation.
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Adverse events not covered by the National Cancer 
Institute Common Terminology Criteria for Adverse Events 
criteria were graded according to a three-point system: mild, 
moderate, and severe.
Statistical Methods
The efficacy of the treatment was evaluated using 
Simon’s two-stage minimax design where the endpoint vari-
able was pCR. The null hypothesis was that the probability of 
pCR was 0.20. The alternative hypothesis was that the pCR 
was 0.35. A type I error of 0.10 and a type II error of 0.20 were 
selected. A total of 22 patients were enrolled in the first stage, 
and at least five pCRs were required to enroll an additional 19 
patients in the second stage. If the number of pCRs exceeded 
11, then the alternative hypothesis would be accepted.
During the first stage of the efficacy analysis, the impact 
of any nonhematologic toxicities exceeding grade 2 would be 
assessed with two sets of stopping rules, one for grade 4 toxici-
ties and another for grade 3 or grade 4 toxicities. If the boundar-
ies of grade 3 or 4 toxicities were reached (i.e., 5 of 22 patients) 
in the first phase of the trial, the study would be terminated.
RESULTS
The characteristics of the patients enrolled in the study 
are delineated in Table 1. The majority of the patients were 
men (93%), median age was 64 years, and they had an ECOG 
performance status of 0 to 1 (95%); patients had a histology 
of adenocarcinoma (78%), and tumors were located in the 
esophagus (63%).
Drug Exposure
Cetuximab was given at day −14 (loading dose), day −7, 
chemoradiation therapy week 1 to week 6, all together 8 weeks. 
Thirty-seven patients (90%) received 8 weeks of cetuximab. 
Radiation therapy was given during chemoradiation therapy 
week 1 to week 6, all together 6 weeks. Thirty-nine patients 
(95%) received 6 weeks of radiation therapy. Patients who 
completed treatment per protocol were either those who com-
pleted 8 weeks of cetuximab and 6 weeks of radiation therapy 
or those who missed part of the per protocol treatment but 
underwent the surgery. Thirty-nine patients (95%) completed 
the study treatment (Table 2).
Dose Modification and Dose Delay
Please refer to Table 3. Cetuximab required dose modi-
fication because of toxicity (17%), planned per protocol 
(5%), or because of intercurrent illness (2%). Cetuximab was 
delayed because of toxicity (10%), intercurrent illness (2%), 
or scheduling (5%). The dose of radiation therapy was modi-
fied because of toxicity (7%) or scheduling (24%).
TABLE 1.  Patient Characteristics
Characteristics Category/Statistics n/Value %
Sex Female 3 7
Male 38 93
Race White 36 88
Black or African American 4 10
Unknown 1 2
Ethnicity Hispanic or Latino 2 5
Non-Hispanic 37 90
Not reported 2 5
Age Median 64
Minimum 50
Maximum 82
Mean 64.5
SD 6.9
PS 0 26 63
1 13 32
2 2 5
Tumor site Esophagus 26 63
Gastroesophageal junction 15 37
Disease stage IIA 10 24
IIB 7 17
III 22 54
IVA 2 5
Histology Squamous cell carcinoma 9 22
Adenocarcinoma 32 78
ITT population (n = 41).
PS, performance status; ITT, intent-to-treat.
TABLE 2.  Study Treatment Compliance
Patients Treated
Cetuximab Radiation 
Therapy
N = 41 (%) N = 41 (%)
Number of weeks receiving treatment
 0 1 (2)
 1 1 (2) 1 (2)
 3 1 (2)
 4 1 (2)
 7 1 (2)
 6 39 (95)
 8 37(90)
Statistical summary of weeks protocol treatment received
 Median 8 6
 Minimum 1 0
 Maximum 8 6
 Mean 7.6 5.7
 SD 1.4 1.2
Total number of patients who completed 
protocol treatment
39 (95)
TABLE 3.  Dose Delay
Drug Dose Delay n %
Cetuximab Toxicity 4 10
Intercurrent illness 1 2
Scheduling (patient or site) 2 5
ITT population (n = 41).
ITT, intent-to-treat.
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Patients came off study if protocol-defined follow-up 
was completed (56%), if there was symptomatic deteriora-
tion (10%), or if they were lost to follow-up (7%), had died 
because of disease progression (5%) or other causes (5%), or 
for other reasons, that is, disease progression after restaging 
evaluation and before surgery (17%).
Toxicity
Table 4 shows grade 3 toxicities seen in more than 5% 
of patients. No grade 4 toxicities occurred in more than 5% of 
patients, and one grade 5 toxicity occurred in 2% of patients. 
Each occurrence of toxicity is the highest level each patient 
reported, irrespective of causality attributed. The most fre-
quent toxicity for all grades was dysphagia (88%) followed 
by acneiform rash (76%), nausea (46%), and fatigue (39%). 
The most frequent grade 3 toxicities occurring in more than 
5% of patients were dysphagia (17%), dehydration (7%), and 
anorexia (7%). Grade 5 toxicities included aspiration and 
infection, each reported in one patient (2%).
Four patients died during the study, two because of dis-
ease progression, one because of aspiration pneumonia after 
surgery, and one because of septic shock.
Pathological Response
Thirty-one patients (76%) underwent esophagectomy. 
Of these, 15 (48%) had a pathologic complete response (pCR; 
95% confidence interval [CI], 30%–67%), and 16 (52%) had 
no pCR ; 95% CI, 33%–70%). The pCR percentage rate was 
higher in earlier-stage disease and in patients with squamous 
histology (Table 5). There was no significant difference in pCR 
for tumors of the esophagus (35%) versus GE junction (40%).
Ten patients (24%) patients did not have surgery. Seven 
had metastatic disease on restaging evaluation before surgery 
and were taken off study. One patient was taken off study 
because of treatment-related complications, one patient devel-
oped bilateral lower extremity critical lower limb ischemia, 
and one declined surgery after a restaging positron emission 
tomography scan revealed no evidence of active disease. 
Thirty-six patients (88%) reported dysphagia while on the 
study. Twenty-six patients (63%) reported dysphagia relief.
DISCUSSION
In this phase II study, the addition of cetuximab to exter-
nal beam radiation therapy in patients with potentially resect-
able esophageal cancers resulted in a pCR rate of 36.6% by 
intention-to-treat analysis and 48% in patients who had esoph-
agectomy. Patients with earlier-stage of disease and squamous 
histology had a higher percentage of pCR. The combina-
tion regimen was well tolerated; the most frequent toxicities 
included rash, nausea, and fatigue, with more than 90% of 
patients completing the scheduled treatment before surgery.
pCR as a surrogate marker of improved clinical out-
come has been reported in several studies and has been the 
subject of a recent meta-analysis.10 Scheer et al.10 reported a 
meta-analysis on the effect of pCR on overall survival. The 
patients with tumors that went into a pCR had a median over-
all survival of 37.4 months versus 19.6 months (p = 0.011) for 
patients with persistent disease after combined chemotherapy 
and radiation therapy. Thus, the pCR rate seems to be a valid 
clinical surrogate endpoint for studies with chemotherapy and 
radiation therapy in esophageal cancers.
The role of neoadjuvant chemotherapy and radiation 
therapy in patients with potentially resectable esophageal 
adenocarcinomas and squamous cell carcinomas has been 
the subject of large phase III randomized studies with mixed 
results. Walsh et al.2 randomized 113 patients with resectable 
esophageal adenocarcinoma to surgery or cisplatin/5FU and 
radiation therapy to 40 Gy followed by surgery. The pCR rate 
was 25%. Surgical mortality was reported as 12% and 4% 
in the experimental and control arm, respectively with esti-
mated survival of 32% versus 6% at 3 years. In the Cancer 
and Leukemia Group B 9781 study,3 475 eligible patients were 
planned to be randomized to esophagectomy with lymph node 
dissection or trimodality therapy followed by esophagectomy. 
The study was closed prematurely because of poor accrual 
after 56 patients were enrolled (30 in the trimodality therapy 
arm and 26 in the surgery-only arm). The pCR rate in the tri-
modality arm of the study was 40% in patients with available 
data and 33.3% by intention-to-treat analysis. Two patients 
(7.7%) in the trimodality arm did not have surgery, because 
of evidence of metastatic disease. The median survival (4.48 
versus 1.79 years) and 5-year survival (39% versus 16%) 
favored the trimodality arm of the study over surgery alone.3 
Despite the early termination of the study, small sample size, 
and overlapping CIs, the study provides additional evidence 
of the benefit of neoadjuvant trimodality therapy for patients 
with potentially resectable esophageal cancer.
TABLE 4.  Grade 3 Toxicities ≥5% Irrespective of Causality 
Attributed
CTCAE
Grade 3
N %
Anorexia 3 7
Dehydration 3 7
Dysphagia 7 17
Dyspnea 2 5
Fatigue 2 5
Hypernatremia 2 5
ITT population (n = 41). Grade 4 and 5 toxicities did not occur in ≥5% of patients.
CTCAE, Common Terminology Criteria for Adverse Events; ITT, intent-to-treat.
TABLE 5.  Pathologic Complete Remission by Initial Clinical 
Stage and Histology
Stage or Histology pCR %
IIA 7/10 70
IIB 2/7 29
III 6/22 27
IVA 0/2 0
Adenocarcinoma 9/32 28
Squamous cell 6/9 67
pCR, pathologic complete response.
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Safran et al.11 reported on a phase II clinical trial of 
cetuximab in combination with weekly paclitaxel, carboplatin, 
and radiation therapy for patients with esophageal adenocarci-
nomas. The complete clinical response rate was 70%. Grade 
3 and 4 toxicity included cetuximab-related rash (23%) and 
esophagitis (15%). In a phase Ib/II study,12 28 patients with 
resectable esophageal adenocarcinoma and squamous cell car-
cinomas received two 3-week cycles of cisplatin, docetaxel, 
and cetuximab followed by radiation therapy, weekly cis-
platin, and cetuximab. No limiting toxicity occurred, and 
the three main toxicities included esophagitis, anorexia, and 
fatigue. Surgery was performed in 25 patients. Anastomotic 
leak occurred in three patients. The rate of complete patho-
logic response was 32%, and the event-free and estimated sur-
vival at 12 months was 82% and 86%, respectively.
Leichman et al.13 reported on a phase II clinical trial 
with oxaliplatin, 5-fluorouracil and external beam radiation 
therapy on 93 patients with resectable esophageal and GE 
junction adenocarcinomas. Seventy-three patients (78.5%) 
had esophagectomy, the R0 resection rate was 67.7%, and the 
pCR rate was 28%. The death rate resulting from chemora-
diation therapy or surgery complications while on study was 
4.4%. In a study by Spigel et al.14 on neoadjuvant docetaxel, 
oxaliplatin, capecitabine, and radiation therapy, 31% of the 
patients never made it to surgery because of declining perfor-
mance status, patient request, death, physician decision, and 
disease progression. In our study, 24% (10 of 41) of patients 
with resectable disease did not undergo surgery, 17% (7 of 
41) because of development of metastatic disease on restag-
ing evaluation. Although multiagent chemotherapy seems 
to control micrometastatic disease, the toxicities of the regi-
men result in poor patient tolerance and an increased rate of 
complications.
Although we can only speculate among studies, our 
study compares favorably, the drug regimen was very well tol-
erated, and it had a very high rate of pCRs, raising the question 
of the need for concomitant chemotherapy, radiation therapy, 
and an EGFR-blocking agent. Sequencing of the agents might 
be more appropriate to incorporate chemotherapy into the 
schedule and possibly reduce the rate of systemic recurrence.
Our study has limitations. We did not collect informa-
tion on tumor location and did not perform a complete assess-
ment of dysphagia, which may be helpful information in the 
management of esophageal cancer.
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